Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc. is active in clinical research for melanoma, including previously treated advanced melanoma and untreated advanced melanoma. Its studies also extend to treatment settings where tumor-infiltrating lymphocytes are used alone or alongside immune checkpoint inhibitors.

• Tumor-infiltrating lymphocyte therapy
• Advanced melanoma
• Combination immunotherapy

The sponsor’s melanoma-focused trials include both standalone and combination cell therapy approaches aimed at solid tumor disease control.